Business
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication Significant tumor volume reduction across multiple PDAC models, including orthotopic human and syngeneic systems (p<0.001) Significantly higher tumor and pancreatic tissue accumulation than doxorubicin (p<0.0001), providing a mechanistic basis for Annamycin’s activity where traditional anthracyclines have his
About this update from Moleculin Biotech, Inc.
[{"type":"image","alt":"Moleculin Biotech, Inc.","displaySize":"","headline":null,"caption":"Moleculin Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ygVdJytEJhyRWCgJ6Op6NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1OA--/https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3","width":300,"height":113}},"lazy":false},{"type":"text","content":"Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication","length":189,"tagName":"p"},{"type":"text","content":"Significant tumor volume reduction across multiple PDAC models, including orthotopic human and syngeneic systems (p<0.001)","length":125,"tagName":"p"},{"type":"text","content":"Significantly higher tumor and pancreatic tissue accumulation than doxorubicin (p<0.0001), providing a mechanistic basis for Annamycin’s activity where traditional anthracyclines have historically failed","length":206,"tagName":"p"},{"type":"text","content":"Induced infiltration of CD8+ and CD4+ T cells, suggesting potential to convert immunologically “cold” pancreatic tumors into responders and supporting future combinations with checkpoint and KRAS inhibitors","length":206,"tagName":"p"},{"type":"text","content":"Continues to demonstrate the absence of cardiotoxicity, a well-documented limitation of conventional anthracyclines such as doxorubicin","length":135,"tagName":"p"},{"type":"text","content":"HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 highlighting the potential of its lead drug candidate, Annamycin, in pancreatic cancer. Access the poster here.","length":359,"tagName":"p"},{"type":"text","content":"“We are highly encouraged by these results, which demonstrate compelling anti-tumor activity in pancreatic cancer models. Importantly, these findings are consistent with the effects we continue to observe with Annamycin in AML,” said Walter Klemp, Chairman and Chief Executive Officer...